Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio ...

SMID growth stocks rose in the fourth quarter, benefiting from a post-election rally and the market’s rotation back to growth leadership in December. The Strategy outperformed its benchmark in ...

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an ...

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive ...

During the fourth quarter, U.S. SMID Company Growth Composite Portfolio returned 3.0% gross and 2.7% net of fees, respectively, vs. Russell 2500 Growth Index return of 2.4%. As measured by the ...

A letter outlining “immediate next steps” arrived less than a week after the administration said it was canceling $400 million in grants and contracts. By Katherine Rosman The Trump ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Ranjani Srinivasan’s student visa was revoked by U.S. immigration authorities. That was just the start of her odyssey. By Luis Ferré-Sadurní and Hamed Aleaziz The first knock at the door came ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It held similar amounts of small and mid-caps, in keeping with its smid-cap mandate, so its portfolio centroid tends to stay near the border between the small-growth and mid-growth areas of the ...